Researchers from the National University of Singapore (NUS) have solved a 60-year-old mystery in bacterial cell envelope ...

Dr. Jennifer Schneider discusses Centauri Therapeutics' novel approach to combating Gram-negative infections, its first ...

Antibiotic resistance among Gram‐negative bacteria represents one of the most pressing challenges in modern medicine. These pathogens have evolved multiple mechanisms to evade the effects of ...

A team of US researchers on Sunday said it has identified a way that colistin (a potent, last-resort antibiotic) resistance ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced that the United States Patent and Trademark ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Colistin, a last-resort antibiotic, is losing its power due to rising resistance—and the culprits might be hiding in your ...

Colistin is a potent, last-resort antibiotic used only to treat people with dangerous, life-threatening bacterial infections ...

Colistin is a potent, last-resort antibiotic, used only to treat people with dangerous, life-threatening bacterial infections ...

Background In 2011, there were approximately two million cases of hospital-acquired infections in the United States, more than 75,000 of which were fatal. [1] Gram-negative bacteria cause the four ...